Английская Википедия:ADB-CHMINACA
Шаблон:Short description Шаблон:Drugbox
ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication.[1][2] It was identified in cannabinoid blends in Japan in early 2015.[3]
Side effects
There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.[4][5][6][7][8][9][10][11]
Legal status
In the United States, ADB-CHMINACA is a Schedule I controlled substance.[12] Prior to its listing at the federal level in 2018, Louisiana placed ADB-CHMINACA on its Schedule I list by emergency scheduling in 2014.[13]
Sweden's public health agency suggested to classify ADB-CHMINACA as hazardous substance on November 10, 2014.[14]
ADB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.[15]
ADB-CHMINACA is illegal in Switzerland as of December 2015.[16]
Metabolism
Ten ADB-CHMINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Most transformations occurred at the cyclohexylmethyl tail of the compound.[17]
See also
- 5F-AB-PINACA
- 5F-ADB
- 5F-AMB
- 5F-APINACA
- AB-FUBINACA
- AB-CHFUPYCA
- AB-CHMINACA
- AB-PINACA
- ADB-BINACA
- ADB-FUBINACA
- ADB-HEXINACA
- ADB-PINACA
- ADBICA
- APICA
- APINACA
- MDMB-CHMICA
- MDMB-CHMINACA
- MDMB-FUBINACA
- PX-3
References
Шаблон:Cannabinoids Шаблон:Cannabinoidergics
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite patent
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite news
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite journal